Literature DB >> 32501133

Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?

Anand Anbarasu1, Sudha Ramaiah1, Paul Livingstone2.   

Abstract

The coronavirus disease (COVID-19) is resulting in millions of infected individuals with several hundred thousands dead throughout the world. Amidst all the havoc, one interesting observation in the present COVID-19 pandemic is the negligible symptoms in the young; particularly children below 10 years of age. We assume the extensive pediatric vaccination with MMR vaccines followed globally could have resulted in innate immune responses, e.g., induction of interferons (IFNs) and activated natural killer (NK) cells, thereby offering natural immunity against SARS-CoV-2 in the young population. Possible cross-protective innate immunity offered by MMR vaccination prompted us to suggest repurposing MMR vaccination for immuno-prophylaxis against COVID-19.

Entities:  

Keywords:  COVID-19; MMR Vaccine; SARS-CoV-2; children; innate immunity; prophylaxis

Mesh:

Substances:

Year:  2020        PMID: 32501133      PMCID: PMC7553692          DOI: 10.1080/21645515.2020.1773141

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  5 in total

1.  Side effects of interferon-alpha therapy.

Authors:  Stefan Sleijfer; Marjolein Bannink; Arthur R Van Gool; Wim H J Kruit; Gerrit Stoter
Journal:  Pharm World Sci       Date:  2005-12

Review 2.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Natural killer (NK) cell response after vaccination of volunteers with killed influenza vaccine.

Authors:  J M Schapiro; Y Segev; L Rannon; M Alkan; B Rager-Zisman
Journal:  J Med Virol       Date:  1990-03       Impact factor: 2.327

4.  Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model.

Authors:  Mark J Cameron; Alyson A Kelvin; Alberto J Leon; Cheryl M Cameron; Longsi Ran; Luoling Xu; Yong-Kyu Chu; Ali Danesh; Yuan Fang; Qianjun Li; Austin Anderson; Ronald C Couch; Stephane G Paquette; Ndingsa G Fomukong; Otfried Kistner; Manfred Lauchart; Thomas Rowe; Kevin S Harrod; Colleen B Jonsson; David J Kelvin
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

5.  COVID-19 in children: the link in the transmission chain.

Authors:  Alyson A Kelvin; Scott Halperin
Journal:  Lancet Infect Dis       Date:  2020-03-25       Impact factor: 25.071

  5 in total
  16 in total

Review 1.  Measles, mumps and rubella vaccine and heterologous immunity: a way out of the COVID-19 crisis?

Authors:  Jahnavi Shrivastava; Manish Narang; Sunil Gomber
Journal:  Sudan J Paediatr       Date:  2022

Review 2.  Measles, mumps, and rubella (MMR) vaccine and COVID-19: a systematic review.

Authors:  Moslem Taheri Soodejani; Moslem Basti; Seyyed Mohammad Tabatabaei; Kourosh Rajabkhah
Journal:  Int J Mol Epidemiol Genet       Date:  2021-06-15

3.  BCG vaccination potential for COVID-19: an analytical approach.

Authors:  Mina T Kelleni
Journal:  Hum Vaccin Immunother       Date:  2021-03-26       Impact factor: 3.452

4.  Effectiveness of Booster Measles-Mumps-Rubella Vaccination in Lower COVID-19 Infection Rates: A Retrospective Cohort Study in Turkish Adults.

Authors:  Erhan Yengil; Yusuf Onlen; Cahit Ozer; Mustafa Hambolat; Mehmet Ozdogan
Journal:  Int J Gen Med       Date:  2021-05-07

Review 5.  COVID-19: Why does disease severity vary among individuals?

Authors:  Saeed Samadizadeh; Maha Masoudi; Mostafa Rastegar; Vahid Salimi; Mahsa Bataghva Shahbaz; Alireza Tahamtan
Journal:  Respir Med       Date:  2021-03-05       Impact factor: 4.582

6.  SARS-CoV-2 spike protein displays sequence similarities with paramyxovirus surface proteins; a bioinformatics study.

Authors:  Ehsan Ahmadi; Mohammad Reza Zabihi; Ramin Hosseinzadeh; Leila Mohamed Khosroshahi; Farshid Noorbakhsh
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

Review 7.  COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity.

Authors:  Mi-Hyun Lee; Bum-Joon Kim
Journal:  J Microbiol       Date:  2022-02-14       Impact factor: 2.902

8.  No neutralizing effect of pre-existing tick-borne encephalitis virus antibodies against severe acute respiratory syndrome coronavirus-2: a prospective healthcare worker study.

Authors:  Philipp Kohler; Hulda R Jonsdottir; Rahel Ackermann-Gäumann; Christian R Kahlert; Lorenz Risch; Pietro Vernazza
Journal:  Sci Rep       Date:  2021-12-17       Impact factor: 4.379

9.  Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients.

Authors:  Jeffrey E Gold; William H Baumgartl; Ramazan A Okyay; Warren E Licht; Paul L Fidel; Mairi C Noverr; Larry P Tilley; David J Hurley; Balázs Rada; John W Ashford
Journal:  mBio       Date:  2020-11-20       Impact factor: 7.867

10.  Long-Term Pulmonary Damage From SARS-CoV-2 in an Infant With Brief Unexplained Resolved Events: A Case Report.

Authors:  Luana Nosetti; Massimo Agosti; Massimo Franchini; Valentina Milan; Giorgio Piacentini; Marco Zaffanello
Journal:  Front Med (Lausanne)       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.